Abstract
Purpose
X-linked agammaglobulinemia is a primary humoral immunodeficiency characterized by hypogammaglobulinemia and increased susceptibility to infection. Although there is increased awareness of autoimmune and inflammatory complications in X-linked agammaglobulinemia (XLA), the spectrum of gastrointestinal manifestations has not previously been fully explored.
Methods
We present a case report of a family with two affected patients with XLA. Given the gastrointestinal involvement of the grandfather in this family, we performed a retrospective descriptive analysis of XLA patients with reported diagnoses of GI manifestations and inflammatory bowel disease (IBD) or enteritis registered at the United States Immunodeficiency Network, a national registry of primary immunodeficiencies.
Results
In this cohort of patients with XLA, we found that up to 35% had concurrent gastrointestinal manifestations, and 10% had reported diagnoses of IBD or enteritis. The most commonly reported mutations were missense, which have been associated with a less severe XLA phenotype in the literature. The severity of symptoms were wide ranging, and management strategies were diverse and mainly experimental.
Conclusions
Patients with XLA may require close monitoring with particular attention for GI manifestations including IBD and infectious enteritis. Further studies are needed to improve diagnosis and management of GI conditions in XLA patients.
Similar content being viewed by others
References
Conley ME HV. X-linked agammaglobulinemia [Internet]. GeneReviews® [Internet]. 2011. Available from: http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK1453/
Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, et al. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014;34(6):627–32.
Lee PPW, Chen T-X, Jiang L-P, Chan K-W, Yang W, Lee B-W, et al. Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia. J Clin Immunol. 2010;30(1):121–31.
Conley ME. Genetics of hypogammaglobulinemia: what do we really know ? Curr Opionion Immunol. 2010;21(5):466–71.
Conley ME, Fitch-Hilgenberg ME, Cleveland JL, Parolini O, Rohrer J. Screening of genomic DNA to identify mutations in the gene for Bruton’s tyrosine kinase. Hum Mol Genet. 1994;3(10):1751–6.
Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Bruton’s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001;114(1):141–9.
Tóth B, Volokha A, Mihas A, Pac M, Bernatowska E, Kondratenko I, et al. Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol. 2009;46(10):2140–6.
Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol Orlando Fla. 2006;118(2–3):195–200.
Jones A, Bradley L, Alterman L, Tarlow M, Thompson R, Kinnon C, et al. X linked agammaglobulinaemia with a “leaky” phenotype. Arch Dis Child. 1996;74(6):548–9.
López-Granados E, Pérez de Diego R, Ferreira Cerdán A, Fontán Casariego G, García Rodríguez MC. A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia. J Allergy Clin Immunol. 2005;116(3):690–7.
Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(9):1050–63.
Al-Muhsen SZ. Gastrointestinal and hepatic manifestations of primary immune deficiency diseases. Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc. 2010;16(2):66–74.
Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;46(10):1547–54.
Meyers G, Ng Y-S, Bannock JM, Lavoie A, Walter JE, Notarangelo LD, et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc Natl Acad Sci U S A. 2011;108(28):11554–9.
Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147(5):990–1007.e3.
Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroenterol. 2015;21(43):12296–310.
Shah S, Terdiman J, Gundling K, Mahadevan U. Immunoglobulin therapy for refractory Crohn’s disease. Ther Adv Gastroenterol. 2014;7(2):99–102.
Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn’s disease. Autoimmun Rev. 2012;12(2):275–80.
Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164(Suppl):2–5.
Chan HC-H, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2016;52:141.
Jasion VS, Burnett BP. Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans. Nutr J. 2015;14:22.
Van Arsdall M, Haque I, Liu Y, Rhoads JM. Is there a role for the enteral administration of serum-derived immunoglobulins in human gastrointestinal disease and pediatric critical care nutrition? Adv Nutr Bethesda Md. 2016;7(3):535–43.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Sara Barmettler and Iris M. Otani are shared first co-authors.
Rights and permissions
About this article
Cite this article
Barmettler, S., Otani, I.M., Minhas, J. et al. Gastrointestinal Manifestations in X-linked Agammaglobulinemia. J Clin Immunol 37, 287–294 (2017). https://doi.org/10.1007/s10875-017-0374-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-017-0374-x